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Abstract 
Background: Previous studies suggested a complex association between Toxoplasma Gondii 
(TG) infection and host lipid metabolism. Both TG infection and metabolic disturbances are 
very common in patients with schizophrenia, but this relationship is not clear.  
Methods: In this cross-sectional study, we evaluated the association between TG seropositivity, 
serum lipid levels, body mass index (BMI) and metabolic syndrome (MetS) in 210 male 
inpatients with schizophrenia. 
Results: In our sample of schizophrenia patients, with the mean age of 43.90 ± 12.70 years, the 
rate of TG seropositivity was 52.38% and the prevalence of MetS was 17%. Patients with the 
TG antibodies had lower serum triglyceride levels and body weight compared to TG 
seronegative patients, despite having more frequently received antipsychotics (clozapine, 
olanzapine risperidone and quetiapine), which are well known to induce weight gain and 
metabolic abnormalities. However, the only significant change in metabolic parameters, 
observed in TG seropositive patients with schizophrenia, was decreased serum triglyceride to 
high-density lipoprotein cholesterol (HDL-C) ratio. No associations were observed between TG 
seropositivity and serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) 
and glucose levels, waist circumference, BMI and the rate of MetS. 
Conclusion: This is the first report of the association between TG infection and decreased serum 
triglyceride to HDL-C ratio in a sample of carefully selected men with chronic schizophrenia. 
 
Key words: Toxoplasma Gondii infection; schizophrenia patients; serum lipid indices; body 
mass index; metabolic syndrome 
 
 
 
3 
 
1. Introduction 
Latent infection with Toxoplasma Gondii (TG) has recently raised significant interest in 
psychiatry, particularly in patients with schizophrenia [1,2]. Schizophrenia is a devastating 
disorder, which was consistently associated with increased rates of TG infection [2], but also 
with dyslipidemia [3,4]. Preclinical studies have reported a complex association between TG 
infection and host lipid metabolism. The parasite accumulates lipids from the host low-density 
lipoprotein cholesterol (LDL-C) [5]. Given that, TG is unable to synthesize cholesterol; its 
growth is dependent on the external cholesterol sources. Consequently, infection with TG 
decreased serum total cholesterol (TC) concentration in apolipoprotein E-deficient mice [6], 
LDL-C receptor knockout mice fed with hypercholesterolemic diet [5] and in wild-type mice 
[7]. In general, TG infection reduced serum TC levels in animal models due to its increased 
uptake [6].  
In spite of such profound effects of TG on lipids in animal models, only two studies 
have investigated lipid levels in human subjects with evidence of TG infection. One study found 
no difference in serum TC levels from cord blood samples between TG seropositive and 
seronegative pregnant women [8]. Another study reported a correlation between TG 
seropositivity and serum TC and LDL-C levels in men with schizophrenia [9]. However, the 
latter study provided no data on other factors, which affect serum lipid levels in patients, like 
antipsychotics [4,10], lipid-lowering-agents and severity of symptoms.  
Therefore, the link between the TG seropositivity, serum lipid levels and weight is 
poorly understood in patients with schizophrenia. In addition, there is no data on the relationship 
between TG infection and metabolic syndrome (MetS), neither in healthy individuals nor in 
psychiatric patients.  
The aim of this study was to investigate the association between TG seropositivity, 
serum lipid indices, body mass index (BMI) and MetS in men with schizophrenia.  
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2. Materials and methods 
2.1.Subjects and clinical evaluation 
This cross-sectional study was conducted at University Hospital Centre Zagreb, 
Department of Psychiatry, and Psychiatric Hospital Popovaca. Inclusion criteria were: male 
inpatients aged 18 to 65 years, diagnosed with schizophrenia for at least 5 years. Diagnosis of 
schizophrenia was confirmed using the Structured Clinical Interview (SCID) [11]. Exclusion 
criteria were: intellectual disability, patients with first-episode psychosis and/or no previous 
treatment with antipsychotics, substance abuse and dependence in the previous year, any 
comorbid severe somatic or neurological disorder, including inherited dyslipidemia and current 
infection, treatment with lipid-lowering, antidiabetic and /or antihypertensive agents and the 
use of antidepressants in previous three months. 
Only male patients were enrolled in the study in order to exclude the influence of gender 
on the results. Notably, gender differences were reported in metabolic issues, such as obesity 
[12], lipid levels [13], the prevalence of MetS [14], and treatment-outcome [15] in patients with 
schizophrenia. Patients were evaluated using structured interview for the Positive and Negative 
Symptom Scale (PANSS) [16], including the PANSS positive, negative, general 
psychopathology and cognitive (PANSS-COGN) subscale (consisting of P2, N5, N7, G7, G10, 
G11, G12, G14 and G15 PANSS items), as well as with Calgary Depression Scale for 
Schizophrenia (CDSS) [17] and International Suicide Prevention Trial (InterSePT) Scale [18]. 
At the time of the assessment, psychiatrists were not aware of the laboratory test results. 
The study was approved by the local Ethics Committees and was carried out in accordance with 
the Helsinki declaration (1975). All patients have signed approved informed consent prior to 
study procedures. 
 
2.2.Determination of TG IgG antibodies 
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TG immunoglobulin G (IgG) antibodies in serum were determined using VIDAS Toxo 
IgG test produced by Biomerieux, France. Vidas Toxo IgG is an automated quantitative test for 
use on the VIDAS family instruments for the quantitative measurement of anti-TG IgG in 
human serum or plasma using ELFA (Enzyme-Linked-Fluorescent Assay) technique. The assay 
combines a two-step enzyme immunoassay sandwich method with a final fluorescent detection 
at 450 nm. Once the assay is completed, the results are analysed automatically by the instrument 
using calibration curves, which are stored and expressed in international units (IU)/ml. The cut 
off values are determined by the test kit manufacturer. It has been considered that results up to 
4 IU/ml were negative, results from 4 IU/ml to 8 IU/ml were considered equivocal, and results 
above 8 IU/ml were considered positive. 
 
2.3.Determination of biochemical and anthropometric parameters 
Waist and hip circumference (cm), height (cm), and body mass (kg) were measured by 
hospital nursing stuff. The height and weight were recorded in standing position, barefoot, and 
in light clothes. Body mass index (BMI) was calculated as body weight in kilograms divided 
with squared height value in metres. Waist circumference was measured at minimal respiration 
at the high point of the iliac crest and at the level of the umbilicus. 
Venepuncture was performed between 7 and 9 a.m., after 12 h overnight 
fast. Immediately after collecting, blood samples were transferred to the Department for 
Laboratory Medicine, University Hospital Centre Zagreb. Serum levels of triglycerides, TC, 
LDL-C, high-density lipoprotein cholesterol (HDL-C) and glucose were determined on Roche 
Cobas C501 Chemistry Analyzer. Serum glucose level was determined by enzymatic UV test 
with hexokinase. LDL-C was calculated using the Friedewald equation. If serum triglyceride 
concentration exceeded 4.52 mmol/L, LDL-C was estimated by homogeneous enzymatic 
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colorimetric test with cholesterol oxidase. LDL-C/HDL-C, TC/HDL-C and triglycerides/HDL-
C ratios have been also calculated. 
MetS definition was used according to NCEP ATP III criteria [19], which requires the 
presence of three or more of the following criteria: 1) abdominal obesity (waist circumference 
>102 cm in men); 2) hypertriglyceridemia (≥ 1.7 mmol/l); 3) low HDL-cholesterol (< 1.04 
mmol/l in men); 4) high blood pressure (≥ 135/85 mm Hg); 5) high fasting glucose (≥ 6.1 
mmol/l). 
 
2.4.Statistical analysis 
Statistical analyses were performed with GraphPad Prism version 4.00 (GraphPad 
Software, San Diego, CA, USA) and MedCalc Statistical Software version 14.8.1 (MedCalc 
Software bvba, Ostend, Belgium).  
Normality of data distribution was assessed with the D’Agostino-Pearson omnibus 
normality test. The differences in the age, the scores on the PANSS total, positive, negative, 
cognitive and general psychopathology subscales, CDSS and InterSePT total scores, dose of 
antipsychotics expressed as chlorpromazine equivalent, glucose, TC, HDL-C, LDL-C and 
triglyceride levels in the blood, LDL-C/HDL-C, TC/HDL-C and triglycerides/HDL-C ratios, as 
well as the differences in the waist and hip circumference, body weight, and BMI (all expressed 
as mean ± SD), between TG seropositive and TG seronegative group were analysed by Student 
t-test (when data showed normal distribution) or by Mann-Whitney test (when normality of the 
data failed).  
The frequencies of smoking, current treatment with clozapine or olanzapine or 
risperidone or quetiapine, as well as MetS, between different groups of patients with 
schizophrenia were evaluated by a χ2-test of independence.  
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G*Power 3 Software was used for conducting power analyses, i.e. to determine a priori 
sample size and power. For Mann-Whitney test (with α=0.05; power (1−β)=0.80; median effect 
size=0.35), total desired sample size was 210, and the actual sample size was 210. For Student 
t-test (with α=0.05; power (1−β)=0.80; median effect size=0.35), total desired sample size was 
204, and the actual sample size was 210. For analyses with a χ2-test (with α=0.05; power 
(1−β)=0.80 and small effect size (ω=0.20; df =1), total desired sample size was 197, while the 
actual total sample size was 210. Therefore, power analysis revealed that the study included 
appropriate sample size and statistical power to detect significant differences. 
The results obtained by investigating various demographic and clinical data in TG 
seropositive and TG seronegative schizophrenia patients (Table 1) were corrected for multiple 
testing (11 tests) using Bonferroni correction, and the p-value was set to 0.0045. Bonferroni 
correction for multiple testing was also applied to the results obtained by comparing different 
metabolic parameters (13 tests) between TG seropositive and TG seronegative group of patients 
with schizophrenia (Table 2) and the p-value for these data was set to 0.00385. 
Finally, multiple regression analysis (Table 3, Supplementary Table) was performed in 
order to assess the influence of various demographic and clinical data (independent variables), 
listed in the Table 1, on the 13 different metabolic parameters (dependent variables), listed in 
the Table 2, in TG seropositive and TG seronegative patients with schizophrenia, and the p-
value for these analysis was set to 0.00385. 
 
3. Results 
The study enrolled 210 male patients, with the mean age of 43.90 ± 12.70 years. The 
rate of TG seropositivity in the entire sample of our patients was 52.38% (110/210), which is 
higher compared to data from the same geographical region, such as 29.10% in healthy Croatian 
women [20] and 36.40% in the general population from southern Croatia [21]. This finding 
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supports the compelling evidence, that despite huge differences in TG seroprevalences across 
countries [22], patients with schizophrenia consistently have higher rates of TG seropositivity 
than subjects from the appropriate general population [23-26]. 
Demographic and clinical features of TG seropositive and TG seronegative patients are 
presented in Table 1. Patients with TG antibodies were significantly older (p<0.0001, Mann-
Whitney test). As presented in Table 1, TG seropositive and TG seronegative patients did not 
differ significantly in the number of PANSS total, positive, negative and general 
psychopathology scores and frequency of smoking. TG seropositive patients had nominally 
significantly higher number of InterSePT total scores (p=0.0462; Mann-Whitney test), and 
CDSS total scores (p=0.0148; Mann-Whitney test), when compared to TG seronegative 
patients. 
Regarding antipsychotic treatment, TG seropositive and TG seronegative patients did 
not differ significantly in total current dose of antipsychotics, expressed as chlorpromazine 
equivalent, but TG seropositive group more often received clozapine, olanzapine, risperidone 
or quetiapine (p=0.0099; 2 –test), antipsychotics which were the most commonly associated 
with metabolic abnormalities [19] (Table 1). However, except for age, all other nominally 
significant results have not survived the multiple testing corrections. 
As presented in Table 2, TG seropositive patients had nominally significantly higher 
HDL-C levels (p=0.0111; Student t-test), nominally significantly lower triglycerides levels 
(p=0.0193; Mann-Whitney test), as well as significantly lower triglycerides to HDL-C ratio 
(p=0.0019; Mann-Whitney test). Patients with the presence of TG antibodies also had 
significantly lower hip circumference (p=0.0037; Mann-Whitney test) and nominally 
significantly lower body weight (p=0.0354; Student t-test). Blood glucose, TC and LDL-C 
levels, as well as LDL-C to HDL-C ratio, TC to HDL-C ratio, waist circumference and BMI 
did not differ between TG seropositive and TG seronegative patients (Table 2). The prevalence 
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of MetS among patients was 17.14 % (36/210), but the distribution of MetS was similar in TG 
seropositive and TG seronegative groups (p=0.4960; 2–test). 
As shown in Table 3 and Supplementary Table, multiple regression analysis 
demonstrated nominally significant influence of TG seropositivity on triglyceride levels 
(p=0.0289), hip circumference (p=0.0148), as well as on the body weight (p=0.0222). In 
addition to TG infection, multiple regression analysis revealed dose of antipsychotics, 
expressed as chlorpromazine equivalent, as one of the major variables nominally influencing 
the triglyceride to HDL-C ratio (p=0.0483), but significantly affecting waist circumference 
(p=0.0015), hip circumference (p=0.0007), body weight (p<0.0001) and BMI (p=0.0004) 
(Table 3, Supplementary Table). Moreover, multiple regression analysis (Table 3, 
Supplementary Table) identified that current treatment with clozapine, olanzapine, risperidone 
or quetiapine nominally influenced LDL-C levels (p=0.0468); CDSS total scores were 
significantly associated with triglyceride levels (p=0.0021) and nominally associated with waist 
circumference (p=0.0492); whereas smoking status nominally affected hip circumference 
(p=0.0194). 
 
4. Discussion 
The main finding of the present study is that TG seropositive patients with schizophrenia 
had significantly lower triglyceride to HDL-C ratio compared to TG seronegative patients. 
Differences between TG seropositive and TG seronegative patients with schizophrenia, 
determined in many other metabolic parameters, such as HDL-C and triglycerides levels, as 
well as body weight, were only nominally significant, i.e. have not survived the Bonferonni 
correction for multiple testing. 
  
4.1.TG seropositivity and serum lipid levels 
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The only study that addressed so far serum lipid levels in patients with schizophrenia 
according to TG status, has reported increased concentrations of serum TC and LDL-C in TG 
infected men, and no differences in any lipid indices in women with schizophrenia [9]. The 
discrepancies [9, present study] might be attributed to types of antipsychotics, diet habits, 
physical activity and lower number of male participants in the aforementioned study [9] 
compared to our study (79 vs 210, respectively).  
Antipsychotics markedly differ in their propensities to affect serum triglyceride levels. 
In animal models, olanzapine has elevated serum triglyceride levels [27], whereas haloperidol 
[28] and aripiprazole [27,28] induced no changes. In first-episode patients, olanzapine has also 
increased serum triglycerides [4,10], TC and LDL-C levels [10], while risperidone elevated 
serum TC and LDL-C levels [10]. In our sample, TG seropositive patients more frequently 
received antipsychotics with higher risk of hyperlipidemia such as clozapine, olanzapine, 
risperidone and quetiapine [29]. In contrast to Pearce et al. [30], who demonstrated that TG 
seroprevalence is not elevated in unipolar mood disorders, in our study TG seropositive patients 
had nominally higher depression scores. Given that second-generation antipsychotics, such as 
olanzapine, quetiapine and clozapine [31], are slightly more effective in treating depressive 
symptoms in patients with schizophrenia, the attending psychiatrists might have prescribed 
those drugs in order to alleviate symptoms of depression. 
On the other hand, despite higher prescription of antipsychotics with increased risk of 
hyperlipidemia, TG seropositive patients in our study had lower triglyceride levels, compared 
to TG seronegative patients. Although nominally significant, this finding might be of clinical 
significance; given that our TG seropositive patients had serum triglyceride levels below, while 
TG seronegative patients had triglyceride levels above the recommended limit of 1.7 mmol/l 
[19]. 
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Since, in addition to lower triglyceride levels, TG seropositive patients in our study also 
had nominally higher HDL-C levels, it is not surprising that their triglyceride to HDL-C ratio 
was significantly lower in comparison to TG seronegative group. Although previous study has 
not found an association of HDL-C levels with TG seropositivity in patients with schizophrenia 
[9], this is the first report on TG/HDL-C ratio according to TG status. As high triglyceride to 
HDL-C ratio was positively associated with metabolic syndrome, insulin resistance and 
dyslipidemia in general population [32] and patients with schizophrenia [33], likelihood of 
carotid plaques in postmenopausal women [34], adverse cardiovascular outcomes in general 
population [35], as well as with cardiovascular disease mortality in men [36], TG seropositive 
patients appear to have more favorable lipid profile. The triglyceride/HDL ratio has been also 
shown as useful surrogate to identify subjects with more atherogenic small LDL particles in 
non-diabetic patients with schizophrenia [33]. However, although infection with TG was found 
to have complex influence on atherosclerosis [6], our study has not investigated atherosclerosis. 
Given the utmost importance of atherosclerosis in modern world, it remains to be determined 
if and how TG infection affects the development of atherosclerosis in schizophrenia. 
There is also evidence linking TG infection to suicidality, although the exact 
mechanisms are not clear [37]. Subjects with recent suicide attempt had lower triglyceride 
levels compared to patients who did not attempt suicide [38]. Our TG seropositive patients had 
nominally higher current suicidality, as reflected in their increased InterSePT scores. As 
clozapine is shown to reduce suicidal behavior in patients with schizophrenia [39], and so far 
is the only antipsychotic registered by both FDA and EMA for the reduction of the risk for 
suicidal behavior, this might be the explanation for more frequent clozapine treatment among 
TG seropositive patients. However, multiple regression analysis confirmed only significant 
association between CDSS total scores (measuring depression) and triglyceride levels. 
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Patients with schizophrenia also have poor diet habits. However, all our inpatients 
received similar, standardized hospital diet. Physical activity could reduce triglyceride levels in 
patients with schizophrenia [40]. Although patients with schizophrenia have sedentary lifestyle, 
it cannot be excluded that TG seropositive patients in the current study were more physically 
active than TG seronegative patients. Notably, TG infection was found to increase activity 
levels in infected compared to non-infected rats [41] and more recent study has reported 
elevated open field activity in mice infected with TG [42]. 
 
4.2.TG seropositivity and weight 
Patients in TG seropositive group had nominally lower body weight compared to 
seronegative patients. Lower body weight was reported in TG seropositive pregnant women 
compared to seronegative women [43]. These findings might suggest that TG infection 
decreases appetite and/or increases activity. Animal data also revealed decreased body weight 
during TG infection [5]. Decreased appetite was reported in animals [44] and in 83.3% of 
hospitalized subjects [45] acutely infected with TG, but it is unknown whether TG infection 
decreases appetite of patients with schizophrenia. Lower body weight in TG seropositive 
patients could be another reason for prescribing metabolically active antipsychotics in this 
population, i.e., psychiatrists might have been less reluctant to give such drugs to patients with 
lower weight. 
 
4.3.TG seropositivity and MetS 
The prevalence of MetS of 17 % in our entire sample was unusually low compared to 
other patients with schizophrenia [3], particularly those treated with clozapine (51.9 %), 
olanzapine (28.2 %) and risperidone (27.9 %) [3]. 
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Given that age, duration of the disease and treatment with antipsychotics increase the 
chances of having MetS [3], our patients were even more prone for MetS. The low prevalence 
of MetS observed in our sample might be related to narrow inclusion criteria. 
 
4.4.Study limitations and strengths 
This study is limited by cross-sectional design which precludes any causal assessments. 
Data on physical activity, appetite and eating habits were not collected. Concentrations of 
antipsychotics were not determined. Our findings might not be generalizable to women with 
schizophrenia, first-episode patients, drug-naïve patients, outpatients who are in stable 
condition and those with significant medical comorbidities. 
Most results in our study were only nominally significant i.e. have not survived 
Bonferonni correction for multiple testing. However, it should be noted that the Bonferroni 
correction can be conservative if there are a large number of tests and/or the test statistics are 
positively correlated. Therefore, the Bonferonni correction might increase the probability of 
producing false negatives, i.e., reducing statistical power. On the other hand, the study has 
several strengths such as the inclusion of carefully selected, ethnically homogenous Caucasian 
group of male chronic inpatients with schizophrenia. All patients were evaluated by the same 
rater. The study had adequate statistical power and sample size. 
 
5. Conclusions 
Data presented here suggest that TG seropositive male inpatients with chronic 
schizophrenia, in spite of being older and receiving more often antipsychotics known to induce 
metabolic adverse events, have lower triglyceride levels and body weight, compared to TG 
seronegative patients. However, the only significant change in metabolic parameters, observed 
in TG seropositive patients with schizophrenia, was decreased serum triglyceride to HDL-C 
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ratio. Due to the cross-sectional design, it is not possible to conclude if TG infection directly 
influenced these metabolic parameters due to host-parasite interaction, or just affected drug-
compliance, appetite, food intake and physical activity. Future studies are needed to determine 
whether TG infection relates to more favorable metabolic profile in patients with schizophrenia. 
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Table 1. Demographic and clinical data of patients with schizophrenia subdivided into TG 
seropositive and TG seronegative groups 
 TG seropositive 
group (N=110) 
TG seronegative 
group (N=100) 
 
Mean age (years)  
(mean ± SD) 
48.49 ± 11.90  39.72 ± 11.99 t=5.314; df=208; 
P<0.0001;  
Student t-test 
Smoking  
N (%) 
74 (67.27) 68 (68.00) 2= 0.01265; df=1;  
P= 0.9104; 2-test 
PANSS total score  
(mean ± SD) 
107.50 ± 16.99 110.30 ± 18.10 U=5010; P=0.2659; 
Mann-Whitney test 
PANSS positive score 
(mean ± SD) 
24.02 ± 5.53 25.11 ± 6.78 U=5076; P=0.3351; 
Mann-Whitney test 
PANSS negative score 
(mean ± SD) 
29.42 ± 5.67 30.02 ± 5.88 U=5201; P=0.4962; 
Mann-Whitney test 
PANSS general 
psychopathology score 
(mean ± SD) 
55.22 ± 8.35 55.47 ± 9.45 U=5437; P=0.8857; 
Mann-Whitney test 
PANSS-COGN score 
(mean ± SD) 
36.43 ± 5.65 35.82 ± 6.24 U=5100; P=0.3627; 
Mann-Whitney test 
CDSS total score 
(mean ± SD) 
7.82 ± 4.50 6.30 ± 3.84 U=4435; P=0.0148 
Mann-Whitney test 
InterSePT total score 
(mean ± SD) 
3.99 ± 3.88 2.80 ± 2.76 U=4634; P=0.0462 
Mann-Whitney test 
Dose of antipsychotics 
(chlorpromazine 
equivalent) (mean ± SD) 
877.2 ± 313.0 863.6 ± 422.1 t=0.2651; df=208; 
P=0.7912;  
Student t-test 
Current treatment with 
clozapine/olanzapine/ 
risperidone/quetiapine  
N (%) 
87 (79.09) 63 (63.00) 2=6.646; df=1; 
P=0.0099; 2-test 
CDSS: Calgary Depression Scale for Schizophrenia; InterSePT: International Suicide 
Prevention Trial; Scale N: number of subjects; PANSS: Positive and Negative Symptom Scale; 
PANSS-COGN: PANSS cognitive subscale; SD: standard deviation; TG: Toxoplasma gondii. 
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Table 2. Metabolic parameters of patients with schizophrenia subdivided into TG seropositive 
and TG seronegative groups 
 TG seropositive 
group (N=110) 
TG seronegative 
group (N=100) 
 
Glucose (mmol/L) 
(mean ± SD) 
5.303 ± 1.160 5.288 ± 1.077 U=5224; P=0.5302; 
Mann-Whitney test 
LDL-C (mmol/L) 
(mean ± SD) 
2.875 ± 0.9295 2.973 ± 2.207 U=5196; P=0.4894; 
Mann-Whitney test 
HDL-C (mmol/L) 
(mean ± SD) 
1.166 ± 0.4014 1.029 ± 0.3729 t=2.562; df=208; 
P=0.0111; 
Student t-test 
LDL-C/HDL-C 
(mean ± SD) 
2.722 ± 1.278 3.812 ± 7.444 U=4739; P=0.0836; 
Mann-Whitney test 
TC (mmol/L) 
(mean ± SD) 
4.720 ± 1.069 4.587 ± 1.266 t=0.8249; df=208; 
P=0.4104; 
Student t-test 
TC/HDL-C 
(mean ± SD) 
4.392 ± 1.584 5.692 ± 9.474 U=4768; P=0.0960; 
Mann-Whitney test 
Triglycerides (mmol/L) 
(mean ± SD) 
1.605 ± 0.9535 1.809 ± 1.004 U=4471; P=0.0193; 
Mann-Whitney test 
Triglycerides/HDL-C 
(mean ± SD) 
1.597 ± 1.262 2.206 ± 2.842 U=4144; P=0.0019; 
Mann-Whitney test 
Waist circumference 
(cm) (mean ± SD) 
95.47 ± 14.59 97.49 ± 11.21 t=1.115; df=208; 
P=0.2661; 
Student t-test 
Hip circumference 
(cm) (mean ± SD) 
101.3 ± 13.16 105.5 ± 10.82 U=4221; P=0.0037; 
Mann-Whitney test 
Body weight (kg) 
(mean ± SD) 
80.25 ± 14.61 84.75 ± 16.22 t=2.117; df=208; 
P=0.0354; 
Student t-test 
BMI (kg/m2) 
(mean ± SD) 
25.86 ± 4.070 26.38 ± 4.467 t=0.8896; df=208; 
P=0.3747; 
Student t-test 
MetS 
N (%) 
17 (15.45) 19 (19.00) 2=0.4636; df=1; 
P=0.4960; 2–test 
 
BMI: body mass index; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein cholesterol; MetS: metabolic syndrome; N: number; SD: standard deviation; TC: 
total cholesterol; TG: Toxoplasma Gondii. 
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Table 3. The results (p values) of multiple regression analysis assessing the influence of various demographic and clinical data (independent variables) on the 
individual metabolic parameters (dependent variables) in patients with schizophrenia. Complete statistical data is presented in Supplementary Table. 
DEPENDENT VARIABLES 
INDEPENDENT 
VARIABLES 
Glucose LDL-C HDL-C LDL-C 
/HDL-C 
TC TC 
/HDL-C 
Triglycerides Triglycerides 
/HDL-C 
Waist 
circumference 
Hip 
circumference 
Body 
weight 
BMI MetS 
Mean age 0.0723 0.7131 0.0833 0.3969 0.2277 0.3782 0.9045 0.0668 0.1748 0.2629 0.1633 0.8313 0.8188 
Smoking 0.0989 0.1210 0.1014 0.2322 0.3233 0.3450 0.9694 0.5040 0.2456 0.0194 0.8475 0.9034 0.8786 
TG seropositivity 0.0733 0.1983 0.5984 0.2569 0.2364 0.3095 0.0289 0.0964 0.1079 0.0148 0.0222 0.2223 0.4632 
PANSS total score 0.6307 0.6888 0.9632 0.8565 0.5226 0.9672 0.4521 0.3457 0.7541 0.7705 0.6138 0.6781 0.2359 
PANSS positive 
score 
0.8115 0.4988 0.4184 0.9132 0.6739 0.6929 0.7011 0.2101 0.9840 0.9896 0.5193 0.6682 0.7540 
PANSS negative 
score  
0.2468 0.4671 0.5175 0.7323 0.2653 0.6313 0.1524 0.4618 0.3407 0.7538 0.7160 0.8835 0.0846 
PANSS general 
psychopathology 
score 
0.6183 0.9256 0.7775 0.5189 0.4902 0.5037 0.1338 0.7300 0.2185 0.7813 0.5065 0.5254 0.3120 
PANSS-COGN 
score 
0.5792 0.3027 0.4722 0.3165 0.9260 0.4005 0.3852 0.8895 0.5940 0.7855 0.7991 0.6209 0.7770 
CDSS total score 0.2151 0.8437 0.1158 0.6931 0.0615 0.9905 0.0021 0.3354 0.0492 0.2166 0.1348 0.2415 0.4547 
InterSePT total 
score 
0.3946 0.6758 0.1524 0.9840 0.2132 0.9834 0.0734 0.7599 0.2285 0.2268 0.5351 0.6706 0.6314 
Dose of 
antipsychotics 
(chlorpromazine 
equivalent) 
0.3175 0.1822 0.7689 0.2096 0.1732 0.2345 0.0519 0.0483 0.0015 0.0007 <0.0001 0.0004 0.1284 
Current treatment 
with clozapine/ 
olanzapine/ 
risperidone/ 
quetiapine 
0.5286 0.0468 0.7760 0.1645 0.2113 0.2381 0.0935 0.0951 0.3651 0.1503 0.9614 0.9819 0.7320 
BMI: body mass index; CDSS: Calgary Depression Scale for Schizophrenia; HDL-C: high-density lipoprotein cholesterol; InterSePT: International Suicide 
Prevention Trial Scale; LDL-C: low-density lipoprotein cholesterol; MetS: metabolic syndrome; PANSS: Positive and Negative Symptom Scale; PANSS-COGN: 
PANSS cognitive subscale; TC: total cholesterol; TG: Toxoplasma gondii.  
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Supplementary Table: The results of multiple regression analysis assessing the influence of various demographic and clinical data (independent variables) on 
the individual metabolic parameters (dependent variables) in patients with schizophrenia. 
DEPENDENT VARIABLES 
INDEPENDENT 
VARIABLES 
Glucose LDL-C HDL-C LDL-C 
/HDL-C 
TC TC 
/HDL-C 
Triglycerides Triglycerides 
/HDL-C 
Waist 
circumference 
Hip 
circumference 
Body 
weight 
BMI MetS 
Mean age              
P 
Coefficient 
Std. Error 
rpartial 
t 
0.0723 
0.0399 
0.0221 
0.1277 
1.8070 
0.7131 
0.0044 
0.0119 
0.0263 
0.3680 
0.0833 
0.0077 
0.0044 
0.1231 
1.7410 
0.3969 
-0.0271 
0.0319 
-0.0604 
-0.8490 
0.2277 
0.0176 
0.0146 
0.0859 
1.2100 
0.3782 
-0.0360 
0.0408 
-0.0628 
-0.8830 
0.9045 
-0.0010 
0.0082 
-0.0086 
-0.1200 
0.0668 
-0.0240 
0.0130 
-0.1302 
-1.8430 
0.1748 
0.1059 
0.0778 
0.0966 
1.3620 
0.2629 
0.0809 
0.0721 
0.0797 
1.1230 
0.1633 
-0.1260 
0.0900 
-0.0992 
-1.3990 
0.8313 
0.0055 
0.0256 
0.0152 
0.2130 
0.8188
0.0005 
0.0023 
0.0163 
0.2290 
Smoking              
P 
Coefficient 
Std. Error 
rpartial 
t 
0.0989 
-0.8947 
0.5395 
-0.1173 
-1.6580 
0.1210 
-0.4508 
0.2895 
-0.1103 
-1.5570 
0.1014 
-0.1785 
0.1085 
-0.1165 
-1.6460 
0.2322 
-0.9325 
0.7782 
-0.0851 
-1.1980 
0.3233 
-0.3525 
0.3559 
-0.0704 
-0.9900 
0.3450 
-0.9424 
0.9955 
-0.0673 
-0.9470 
0.9694 
-0.0077 
0.2014 
-0.0027 
-0.0384 
0.5040 
-0.2130 
0.3181 
-0.0476 
-0.6700 
0.2456 
-2.2125 
1.8998 
-0.0827 
-1.1650 
0.0194 
-4.1500 
1.7605 
-0.1656 
-2.3570 
0.8475 
0.4233 
2.1989 
0.0137 
0.1930 
0.9034 
0.0759 
0.6250 
0.0087 
0.1220 
0.8786 
-0.0087 
0.0567 
-0.0109 
-0.1530 
TG seropositivity              
P 
Coefficient 
Std. Error 
rpartial 
t 
0.0733 
-0.9990 
0.5548 
-0.1273 
-1.8010 
0.1983 
-0.3842 
0.2976 
-0.0916 
-1.2910 
0.5984 
-0.0588 
0.1115 
-0.0376 
-0.5280 
0.2569 
-0.9099 
0.8002 
-0.0807 
-1.1370 
0.2364 
-0.4347 
0.3660 
-0.0843 
-1.1880 
0.3095 
-1.0429 
1.0236 
-0.0724 
-1.0190 
0.0289 
-0.4558 
0.2070 
-0.1549 
-2.2010 
0.0964 
-0.5465 
0.3271 
-0.1182 
-1.6710 
0.1079 
-3.1550 
1.9534 
-0.1143 
-1.6150 
0.0148 
-4.4522 
1.8103 
-0.1726 
-2.4590 
0.0222 
-4.6593 
2.0221 
-0.1585 
-2.3040 
0.2223 
-0.7867 
0.6426 
-0.0869 
-1.2240 
0.4632 
-0.0429 
0.0583 
-0.0523 
-0.7350 
PANSS total score 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.6307 
0.0300 
0.0622 
0.0343 
0.4810 
0.6888 
0.0134 
0.0334 
0.0286 
0.4010 
0.9632 
-0.0006 
0.0125 
-0.0033 
-0.0461 
0.8565 
0.0163 
0.0898 
0.0129 
0.1810 
0.5226 
0.0263 
0.0411 
0.0456 
0.6400 
0.9672 
0.0047 
0.1148 
0.0029 
0.0412 
0.4521 
0.0175 
0.0232 
0.0536 
0.7530 
0.3457 
-0.0347 
0.0367 
-0.0672 
-0.9450 
0.7541 
0.0688 
0.2192 
0.0223 
0.3140 
0.7705 
0.0593 
0.2031 
0.0208 
0.2920 
0.6138 
-0.1282 
0.2537 
-0.0360 
-0.5050 
0.6781 
-0.0300 
0.0721 
-0.0296 
-0.4160 
0.2359 
0.0078 
0.0065 
0.0844 
1.1890 
PANSS positive score 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.8115 
-0.0188 
0.0786 
-0.0171 
-0.2390 
0.4988 
-0.0286 
0.0422 
-0.0482 
-0.6780 
0.4184 
-0.0128 
0.0158 
-0.0577 
-0.8110 
0.9132 
0.0124 
0.1134 
0.0078 
0.1090 
0.6739 
-0.0219 
0.0519 
-0.0300 
-0.4210 
0.6929 
0.0573 
0.1450 
0.0282 
0.3950 
0.7011 
-0.0113 
0.0293 
-0.0274 
-0.3840 
0.2101 
0.0583 
0.0463 
0.0892 
1.2570 
0.9840 
0.0055 
0.2767 
0.0014 
0.0200 
0.9896 
-0.0033 
0.2565 
-0.0009 
-0.0130 
0.5193 
0.2068 
0.3203 
0.0460 
0.6460 
0.6682 
0.0391 
0.0910 
0.0306 
0.4290 
0.7540 
-0.0026 
0.0083 
-0.0223 
-0.3140 
PANSS negative score 
P 
Coefficient 
Std. Error 
rpartial 
0.2468 
-0.1062 
0.0914 
-0.0825 
0.4671 
-0.0358 
0.0491 
-0.0518 
0.5175 
-0.0119 
0.0184 
-0.0461 
0.7323 
0.0452 
0.1319 
0.0244 
0.2653 
-0.0674 
0.0603 
-0.0793 
0.6313 
0.0811 
0.1687 
0.0342 
0.1524 
-0.0490 
0.0341 
-0.1018 
0.4618 
0.0398 
0.0539 
0.0525 
0.3407 
-0.3075 
0.3220 
-0.0679 
0.7538 
-0.0937 
0.2984 
-0.0224 
0.7160 
-0.1358 
0.3727 
-0.0260 
0.8835 
-0.0156 
0.1059 
-0.0105 
0.0846 
-0.0167 
0.0096 
-0.1226 
25 
 
t  -1.1620 -0.7290 -0.6480 0.3430 -1.1170 0.4810 -1.4370 0.7370 -0.9550 -0.3140 -0.3640 -0.1470 -1.7330 
PANSS general psychopathology score 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.6183 
-0.0402 
0.0805 
-0.0355 
-0.4990 
0.9256 
-0.0040 
0.0432 
-0.0067 
-0.0934 
0.7775 
0.0046 
0.0162 
0.0201 
0.2830 
0.5189 
-0.0751 
0.1162 
-0.0460 
-0.6460 
0.4902 
-0.0367 
0.0531 
-0.0492 
-0.6910 
0.5037 
-0.0995 
0.1486 
-0.0477 
-0.6700 
0.1338 
-0.0452 
0.0301 
-0.1067 
-1.5060 
0.7300 
-0.0164 
0.0475 
-0.0246 
-0.3460 
0.2185 
-0.3501 
0.2836 
-0.0876 
-1.2340 
0.7813 
-0.0730 
0.2628 
-0.0198 
-0.2780 
0.5065 
-0.2184 
0.3282 
-0.0474 
-0.6650 
0.5254 
-0.0594 
0.0933 
-0.0453 
-0.6360 
0.3120 
-0.0086 
0.0085 
-0.0720 
-1.0140 
PANSS-COGN score 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.5792 
0.0444 
0.0799 
0.0395 
0.5550 
0.3027 
-0.0443 
0.0429 
-0.0734 
-1.0330 
0.4722 
0.0116 
0.0161 
0.0512 
0.7200 
0.3165 
-0.1158 
0.1153 
-0.0714 
-1.0040 
0.9260 
-0.0049 
0.0527 
-0.0066 
-0.0930 
0.4005 
-0.1243 
0.1475 
-0.0599 
-0.8420 
0.3852 
0.0260 
0.0298 
0.0619 
0.8700 
0.8895 
-0.0066 
0.0471 
-0.0099 
-0.1390 
0.5940 
0.1503 
0.2815 
0.0380 
0.5340 
0.7855 
-0.0711 
0.2608 
-0.0194 
-0.2730 
0.7991 
0.0830 
0.3258 
0.0182 
0.2550 
0.6209 
0.0459 
0.0926 
0.0353 
0.4950 
0.7770 
-0.0024 
0.0084 
-0.0202 
-0.2840 
CDSS total score 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.2151 
0.0945 
0.0760 
0.0883 
1.2440 
0.8437 
-0.0081 
0.0408 
-0.0141 
-0.1970 
0.1158 
0.0241 
0.0153 
0.1118 
1.5790 
0.6931 
-0.0433 
0.1096 
-0.0281 
-0.3950 
0.0615 
0.0943 
0.0502 
0.1328 
1.8810 
0.9905 
0.0017 
0.1403 
0.0008 
0.0119 
0.0021 
0.0885 
0.0284 
0.2170 
3.1210 
0.3354 
0.0433 
0.0448 
0.0686 
0.9660 
0.0492 
0.5298 
0.2677 
0.1396 
1.9790 
0.2166 
0.3075 
0.2481 
0.0880 
1.2400 
0.1348 
0.4652 
0.3098 
0.1064 
1.5010 
0.2415 
0.1035 
0.0881 
0.0834 
1.1750 
0.4547 
0.0060 
0.0080 
0.0533 
0.7490 
InterSePT total score 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.3946 
-0.0732 
0.0858 
-0.0607 
-0.8530 
0.6758 
-0.0193 
0.0461 
-0.0298 
-0.4190 
0.1524 
-0.0248 
0.0173 
-0.1018 
-1.4370 
0.9840 
0.0025 
0.1238 
0.0014 
0.0200 
0.2132 
-0.0707 
0.0566 
-0.0886 
-1.2490 
0.9834 
-0.0033 
0.1584 
-0.0018 
-0.0208 
0.0734 
-0.0576 
0.0320 
-0.1272 
-1.8000 
0.7599 
-0.0155 
0.0506 
-0.0218 
-0.3060 
0.2285 
-0.3651 
0.3022 
-0.0858 
-1.2080 
0.2268 
-0.3396 
0.2801 
-0.0861 
-1.2130 
0.5351 
-0.2174 
0.3498 
-0.0442 
-0.6210 
0.6706 
-0.0423 
0.0994 
-0.0303 
-0.4260 
0.6314 
-0.0043 
0.0090 
-0.0342 
-0.4810 
Antipsychotic dose (chlorpromazine equivalent) 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.3175 
0.0007 
0.0007 
0.0712 
1.0020 
0.1822 
0.0005 
0.0004 
0.0950 
1.3390 
0.7689 
0.0001 
0.0001 
0.0209 
0.2940 
0.2096 
0.0013 
0.0010 
0.0893 
1.2590 
0.1732 
0.0006 
0.0005 
0.0969 
1.3670 
0.2345 
0.0015 
0.0013 
0.0847 
1.1930 
0.0519 
0.0005 
0.0003 
0.1380 
1.9560 
0.0483 
0.0008 
0.0004 
0.1401 
1.9870 
0.0015 
0.0080 
0.0025 
0.2232 
3.2140 
0.0007 
0.0079 
0.0023 
0.2394 
3.4610 
<0.0001 
0.01223 
0.0029 
0.2906 
4.2630 
0.0004 
0.0029 
0.0008 
0.2480 
3.5930 
0.1284 
0.0001 
0.0001 
0.1081 
1.5270 
Current treatment with clozapine/olanzapine/ risperidone/quetiapine 
P 
Coefficient 
Std. Error 
rpartial 
t 
0.5286 
0.3469 
0.5496 
0.0449 
0.6310 
0.0468 
0.5899 
0.2949 
0.1411 
2.0010 
0.7760 
0.0315 
0.1105 
0.0203 
0.2850 
0.1645 
1.1061 
0.7927 
0.0989 
1.3950 
0.2113 
0.4547 
0.3626 
0.0890 
1.2540 
0.2381 
1.1999 
1.0140 
0.0840 
1.1830 
0.0935 
0.3457 
0.2051 
0.1192 
1.6850 
0.0951 
0.5435 
0.3240 
0.1187 
1.6770 
0.3651 
-1.7567 
1.9351 
-0.0645 
-0.9080 
0.1503 
-2.5899 
1.7933 
-0.1024 
-1.4440 
0.9614 
-0.1086 
2.2398 
-0.0034 
-0.0485 
0.9819 
0.0145 
0.6366 
0.0016 
0.0227 
0.7320 
0.0198 
0.0578 
0.0244 
0.3430 
BMI: body mass index; CDSS: Calgary Depression Scale for Schizophrenia; HDL-C: high-density lipoprotein cholesterol; InterSePT: International Suicide 
Prevention Trial Scale; LDL-C: low-density lipoprotein cholesterol; MetS: metabolic syndrome; PANSS: Positive and Negative Symptom Scale; PANSS-COGN: 
PANSS cognitive subscale; TC: total cholesterol; TG: Toxoplasma gondii.  
